Chronimed enters court case over Bayer's patents
This article was originally published in Clinica
Diagnostics manufacturer Chronimed is going to court in the US to seek a ruling that its DiaScreen urine test strip does not infringe the patents of Bayer's diagnostic division. In a tit-for-tat retaliation, Bayer filed its own legal action, days later, claiming that Chronimed's DiaScreen does indeed infringe two patents covering Bayer's MULTISTIX line of test strips.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.